Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects

Journal of the American College of Cardiology

Volumn 60, Issue 20, 2012, Pages 2041-2048

  Johannsen, Trine Holm ^a,b   Frikke Schmidt, Ruth ^a,b   Schou, Jesper ^a,b   Nordestgaard, Borge G ^b,c,d   Tybjærg Hansen, Anne ^a,b,d  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

cardiovascular diseases; genetics; lipids; lipoproteins

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; CETP GENE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; COHORT STUDIES; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; QUINOLINES; RISK FACTORS; YOUNG ADULT;

EID: 84868530968     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.07.045     Document Type: Article

References (40)

1. I. Graham, D. Atar, K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2007 2375 2414
2. S.M. Grundy, J.I. Cleeman, C.N. Merz Coordinating Committee of the National Cholesterol Education Program Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
3. M.J. Chapman, H.N. Ginsberg, P. Amarenco European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
4. A.R. Tall, J.L. Breslow, E.M. Rubin Genetic disorders affecting plasma high-density lipoproteins C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly, The Metabolic and Molecular Bases of Inherited Disease 8th edition 2001 McGraw-Hill New York, NY 2915 2936
5. P.J. Barter, M. Caulfield, M. Eriksson ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
6. A.R. Tall CETP inhibitors to increase HDL cholesterol levels N Engl J Med 356 2007 1364 1366
7. A.R. Tall, L. Yvan-Charvet, N. Wang The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 2007 257 260
8. T. Joy, R.A. Hegele Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 7 2008 143 155
9. G.G. Schwartz, A.G. Olsson, C.M. Ballantyne Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome Am Heart J 158 2009 896 901 e3
10. W.E. Boden, J.L. Probstfield, T. Anderson AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
11. R.P. Giugliano Niacin at 56 years of age - time for an early retirement? N Engl J Med 365 2011 2318 2320
12. C.P. Cannon High-density lipoprotein cholesterol as the holy grail JAMA 306 2011 2153 2155
13. C.P. Cannon, S. Shah, H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
14. E.A. Stein, E.M. Roth, J.M. Rhyne, T. Burgess, D. Kallend, J.G. Robinson Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 2010 480 488
15. S.J. Nicholls, H.B. Brewer, J.J. Kastelein Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
16. C. Dachet, O. Poirier, F. Cambien, J. Chapman, M. Rouis New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation Arterioscler Thromb Vasc Biol 20 2000 507 515
17. A.H. Klerkx, M.W. Tanck, J.J. Kastelein Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C>A polymorphism and a novel promoter variant are independently associated with CETP concentration Hum Mol Genet 12 2003 111 123
18. F.V. van Venrooij, R.P. Stolk, J.D. Banga DALI Study Group Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes Diabetes Care 26 2003 1216 1223
19. S.E. Borggreve, H.L. Hillege, B.H. Wolffenbuttel PREVEND Study Group An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study J Clin Endocrinol Metab 91 2006 3382 3388
20. P.A. McCaskie, J.P. Beilby, C.M. Chapman Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease Hum Genet 121 2007 401 411
21. J.F. Thompson, M.E. Lira, L.K. Durham, R.W. Clark, M.J. Bamberger, P.M. Milos Polymorphisms in the CETP gene and association with CETP mass and HDL levels Atherosclerosis 167 2003 195-204
22. A. Thompson, E. Di Angelantonio, N. Sarwar Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
23. R. Sofat, A.D. Hingorani, L. Smeeth Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms Circulation 121 2010 52 62
24. B.G. Nordestgaard, M. Benn, P. Schnohr, A. Tybjærg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
25. R. Frikke-Schmidt, B.G. Nordestgaard, M.C. Stene Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease JAMA 299 2008 2524 2532
26. J.J. Freiberg, A. Tybjærg-Hansen, J.S. Jensen, B.G. Nordestgaard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
27. J. Zacho, A. Tybjærg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, B.G. Nordestgaard Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 2008 1897 1908
28. P.R. Kamstrup, A. Tybjærg-Hansen, R. Steffensen, B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
29. P.M. Ridker, G. Paré, A.N. Parker, R.Y. Zee, J.P. Miletich, D.I. Chasman Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction Genomewide analysis among 18, 245 initially healthy women from the Women's Genome Health Study Circ Cardiovasc Genet 2 2009 26 33
30. S.M. Boekholdt, F.M. Sacks, J.W. Jukema Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects Circulation 111 2005 278 287
31. D.B. Zilversmit Atherogenesis: a postprandial phenomenon Circulation 60 1979 473 485
32. A. Langsted, J.J. Freiberg, A. Tybjærg-Hansen, P. Schnohr, G.B. Jensen, B.G. Nordestgaard Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up J Intern Med 270 2011 65 75
33. A. Varbo, B.G. Nordestgaard, A. Tybjærg-Hansen, P. Schnohr, G.B. Jensen, M. Benn Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population Ann Neurol 69 2011 628 634
34. M.L. Brown, A. Inazu, C.B. Hesler Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins Nature 342 1989 448 451
35. A. Inazu, M.L. Brown, C.B. Hesler Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation N Engl J Med 323 1990 1234 1238
36. J.P. Corsetti, D. Ryan, D.L. Rainwater, A.J. Moss, W. Zareba, C.E. Sparks Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels Arterioscler Thromb Vasc Biol 30 2010 1657 1664
37. D. Corella, P. Carrasco, P. Amiano Common cholesteryl ester transfer protein gene variation related to high-density lipoprotein cholesterol is not associated with decreased coronary heart disease risk after a 10-year follow-up in a Mediterranean cohort: modulation by alcohol consumption Atherosclerosis 211 2010 531 538
38. H. Schunkert, I.R. König, S. Kathiresan for the CARDIoGRAM Consortium Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease Nat Genet 43 2011 333 338
39. T.M. Teslovich, K. Musunuru, A.V. Smith Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
40. Roche Roche Provides Update on Phase III Study of Dalcetrapib [media release] www.roche.com/media/media-releases/med-cor-2012-05-07.htm May 7, 2012 Accessed May 7, 2012